Infervision vs VUNO
A TB screening program has one published figure to work with. A 2025 evaluation of InferRead DR Chest in Lusaka, by independent authors in PLOS Global Public Health, reported 90.3% sensitivity and 39.2% specificity at a 0.12 cut-off, with an AUC of 0.81. VUNO's chest page lists TB among five screening findings, cites an RSNA 2019 abstract and an MFDS trial at Asan Hospital, and gives no accuracy figures. The specificity is low, and VUNO still loses this buyer because its chest page gives no figure to set against it.
In the US the picture reverses. VUNO holds K241439 of November 15, 2024, coded QFM, for triage of pleural effusion and pneumothorax on adult films, while Infervision's six openFDA records cover CT, surgical planning and RECIST software with nothing for DR Chest. A US hospital shopping for a cleared chest X-ray triage tool gets one from VUNO.
VUNO also carries Med-DeepBrain (K231398, October 4, 2023), an MR tool that quantifies brain structures and lesions for a neurology service.
Radiology · Reviewed November 2, 2026
Infervision
by Infervision · founded 2016
AI for CT lung nodules, CT stroke, surgical planning and RECIST follow-up, with FDA clearances for these CT products.
VUNO
by VUNO Inc. · founded 2014
FDA-cleared AI for chest X-ray triage and brain MR volumetry, plus Korean-approved bone age and retinal screening tools.
When to pick each one
Infervision
- Chest X-ray TB screening with a Lusaka evaluation
- Lung nodule CT cleared as K192880
VUNO
- Chest X-ray triage cleared as K241439
- Brain MR volumetry cleared as K231398
- ISO/IEC 27001:2022 and 27701:2019 certificates
Score
Each row shows points earned of points available under the published rubric.
Infervision
57of 100
VUNO
73of 100
| Dimension | Infervision | VUNO | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 18.2 / 18.2 | -5.5 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 6 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Infervision
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
VUNO
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Infervision
FDA decisions
K260973 (opens in new tab)510(k)2026-07-07
InferOperate Suite
K252261 (opens in new tab)510(k)2026-03-13
InferCare RECIST
K250237 (opens in new tab)510(k)2025-09-15
InferOperate Suite
K240554 (opens in new tab)510(k)2025-05-16
InferRead Lung CT.AI
K211179 (opens in new tab)510(k)2021-08-12
InferRead CT Stroke.AI
Show 1 more
K192880 (opens in new tab)510(k)2020-07-02
InferRead Lung CT.AI
Peer-reviewed
4 PubMed records name Infervision.
- Spatial classification of clinical T1a-bN0 non-small cell lung cancer in superior segment based on three-dimensional reconstruction: optimizing surgical margin and operative strategy. (opens in new tab)
- AI-assisted clinico-quantitative imaging nomogram for preoperative malignancy risk in solid and part-solid pulmonary nodules ≤ 3 cm: development and internal validation. (opens in new tab)
- Impact of dose reduction and iterative reconstruction algorithm on the detectability of pulmonary nodules by artificial intelligence. (opens in new tab)
VUNO
FDA decisions
K241439 (opens in new tab)510(k)2024-11-15
VUNO Med-Chest X-ray Triage / VUNO Med-CXR Link Triage
K231398 (opens in new tab)510(k)2023-10-04
VUNO Med-DeepBrain
Peer-reviewed
5 PubMed records name VUNO.
- A comparison of two artificial intelligence-based methods for assessing bone age in Turkish children: BoneXpert and VUNO Med-Bone Age. (opens in new tab)
- Clinical Effectiveness of AI-Based Cardiac Arrest Prediction System for General Ward Patients (VITAL-MD): Protocol for a Multicenter Pragmatic Stepped Wedge Cluster Randomized Controlled Trial. (opens in new tab)
- Combined diagnostic accuracy of two artificial intelligence systems for glaucoma diagnosis using color fundus photography. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Infervision | VUNO |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2016 | 2014 |
| HQ | n/a | KR |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.